和黄医药近期股价经历显著波动，从4月初的暴跌到随后的反弹，再到5月初的连续下跌。特别是5月6日至12日，公司股价出现“五连跌”，最大跌幅近12%。这与武田制药发布的2024财年财报有关，财报显示呋喹替尼销售额在2024财年Q1季度环比下滑7.69%，低于市场预期。尽管呋喹替尼在2024年下半年销售表现超预期，但近期的销售下滑引发了市场担忧，导致和黄医药股价承压。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.